1. Home
  2. AKTX vs IGC Comparison

AKTX vs IGC Comparison

Compare AKTX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • IGC
  • Stock Information
  • Founded
  • AKTX N/A
  • IGC 2005
  • Country
  • AKTX United States
  • IGC United States
  • Employees
  • AKTX N/A
  • IGC N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AKTX Health Care
  • IGC Health Care
  • Exchange
  • AKTX Nasdaq
  • IGC Nasdaq
  • Market Cap
  • AKTX 32.8M
  • IGC 29.4M
  • IPO Year
  • AKTX N/A
  • IGC N/A
  • Fundamental
  • Price
  • AKTX $1.01
  • IGC $0.31
  • Analyst Decision
  • AKTX
  • IGC Strong Buy
  • Analyst Count
  • AKTX 0
  • IGC 2
  • Target Price
  • AKTX N/A
  • IGC $3.75
  • AVG Volume (30 Days)
  • AKTX 29.6K
  • IGC 402.0K
  • Earning Date
  • AKTX 02-24-2025
  • IGC 02-25-2025
  • Dividend Yield
  • AKTX N/A
  • IGC N/A
  • EPS Growth
  • AKTX N/A
  • IGC N/A
  • EPS
  • AKTX N/A
  • IGC N/A
  • Revenue
  • AKTX N/A
  • IGC $1,236,000.00
  • Revenue This Year
  • AKTX N/A
  • IGC N/A
  • Revenue Next Year
  • AKTX N/A
  • IGC $13.38
  • P/E Ratio
  • AKTX N/A
  • IGC N/A
  • Revenue Growth
  • AKTX N/A
  • IGC 1.64
  • 52 Week Low
  • AKTX $0.90
  • IGC $0.27
  • 52 Week High
  • AKTX $4.40
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 39.99
  • IGC 39.72
  • Support Level
  • AKTX $1.10
  • IGC $0.29
  • Resistance Level
  • AKTX $1.33
  • IGC $0.32
  • Average True Range (ATR)
  • AKTX 0.14
  • IGC 0.01
  • MACD
  • AKTX -0.02
  • IGC 0.00
  • Stochastic Oscillator
  • AKTX 1.67
  • IGC 37.75

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: